European Journal of Arrhythmia & Electrophysiology and Heart International are peer-reviewed, free-to-access, bi-annual, journals that aims to provide insightful and topical articles relevant to the day-to-day practice of busy physicians.
The journals are of interest to physicians, healthcare professionals and researchers across Europe and the US, providing practical advice relevant to the clinical setting on diagnosis and treatment in cardiology. European Journal of Arrhythmia & Electrophysiology and Heart International endeavour to support these professionals in continuously developing their knowledge, effectiveness and productivity.
Electronic ISSN: 2036-2579 DOI: doi.org/10.17925
Editors-in-Chief: Dr Magdi El-Omar and Dr Rajesh Davé
Indexing: PubMedCentral (PMC), EBSCO, Web of Science, Google Scholar, Genamics Journal Seek, and IndexCopernicus
Established: 2005 Frequency: Bi-annual
Low-flow, Low-gradient Severe Aortic Stenosis: A Review
Heart International. 2023;17(1):Online ahead of journal publication
The global prevalence of aortic stenosis (AS) has steadily increased over the past several decades.1 In high-income countries, degenerative calcific aortic valve disease is the primary aetiology for AS, whereas chronic rheumatic valve disease and infective endocarditis remain more common causes worldwide.2 Population-wide trends in developed countries suggest a strong relationship between advanced age and incidence of […]
Strategies for Reducing Vascular and Bleeding Risk for Percutaneous Left Ventricular Assist Device-supported High-risk Percutaneous Coronary Intervention
Heart International. 2022;16(2):105–11 DOI: https://doi.org/10.17925/HI.2022.16.2.105
In recent years, patients undergoing non-emergent percutaneous coronary intervention (PCI) procedures have become increasingly older, with a more significant comorbidity burden and complex coronary disease.1 Many of the patients who undergo elective or urgent PCI are surgical turndown patients, for whom PCI is the only revascularization option.2 For these high-risk patients, more interventionalists are opting for […]
Can Percutaneous Coronary Intervention Revive a Failing Heart?
Heart International. 2022;16(2):72–4 DOI: https://doi.org/10.17925/HI.2022.16.2.72
Percutaneous coronary intervention (PCI) has evolved considerably in both technique and technology since Andreas Grüntzig first intervened on a focal, proximal lesion in the left anterior descending artery in 1977.1 While this has resulted in increasingly complex anatomical subsets being treated, contemporary trials of PCI in patients with stable coronary artery disease (CAD) have continued to […]
FOREWORD – HEART INTERNATIONAL – VOLUME 16 ISSUE 2 – 2022
Welcome to the latest issue of Heart International. Cardiovascular science continues to evolve at an impressive rate, and the range of articles presented here highlights cutting-edge technology and innovation within cardiology. We begin with a commentary by Divaka Perera on the REVIVED study, which evaluated whether percutaneous coronary intervention could improve outcomes in patients with […]
Globe Pulsed Field System for High-definition Mapping and Ablation for Atrial Fibrillation
Heart International. 2022;16(2):85–90 DOI: https://doi.org/10.17925/HI.2022.16.2.85
Catheter ablation has emerged as an effective strategy for the treatment of atrial fibrillation (AF), even becoming a first-line option for selected patients.1 Pulmonary vein isolation (PVI) is the cornerstone of this procedure. Ablation beyond PVI is often practised, but scientific evidence from randomized clinical trials is still controversial.2–8 Point-by-point radiofrequency (RF) ablation has been, by […]
Natriuretic Peptide-guided Therapy for Heart Failure
Heart International. 2022;16(2):112–6 DOI: https://doi.org/10.17925/HI.2022.16.2.112
Heart failure (HF) is a complex syndrome caused by a variety of cardiac and non-cardiac diseases, and is associated with high mortality and hospitalization rates.1 Treatment has been traditionally based on a detailed history and physical examination. However, since cardiac biomarkers reflect the pathophysiology of HF, they add information to the clinical findings.1 The most widely used […]
Should Catheter Ablation for Atrial Fibrillation be a Priority in Patients with Heart Failure with Reduced Ejection Fraction?
European Journal of Arrhythmia & Electrophysiology. 2022;8(1):20-4 DOI: https://doi.org/10.17925/EJAE.2022.8.1.20
Heart failure (HF) and atrial fibrillation (AF) are inexorably linked. They frequently coexist and share common risk factors, including ageing, hypertension, diabetes, obesity, sleep apnoea and coronary disease.1–4 Over half of patients with HF develop AF at some point,5 and when AF occurs, it is associated with an increase in total mortality of up to 40%.6 In addition, […]
Foreword – European Journal of Arrhythmia & Electrophysiology, Volume 8, Issue 1, 2022
Welcome to the latest edition of European Journal of Arrhythmia & Electrophysiology. Cardiac arrhythmias, the most common of which is atrial fibrillation, represent a substantial health and economic burden worldwide. In the last two decades we have observed major breakthroughs in the management of arrhythmias, particularly in the field of cardiac electrophysiology, and some of the […]
Mavacamten: A First-in-class Oral Modulator of Cardiac Myosin for the Treatment of Symptomatic Hypertrophic Obstructive Cardiomyopathy
Heart International. 2022;16(2):91–8 DOI: https://doi.org/10.17925/HI.2022.16.2.91
Hypertrophic cardiomyopathy (HCM), along with its more common subgroup, hypertrophic obstructive cardiomyopathy (HOCM), is the most common monogenic cardiovascular disorder, with a prevalence of about 1 in 500,1 and a dominant inheritance pattern, thus clustering in affected families. Patients with HCM often have significant limitations to their exercise capacity, and while there are several underlying pathomechanisms for […]
Journal articles and more to your inbox
Get the latest clinical insights from touchCARDIOSign me up!